Mitchell Ho
Impact in
- Oncology top 1%
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Immunology top 2%
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 49
- Oncology 53
- CAR-T cell therapy research 43
- Co-authors
- Ira H Pastan (30 shared papers)Raffit Hassan (17 shared papers)Wei Gao (18 shared papers)Heungnam Kim (8 shared papers)Mingqian Feng (18 shared papers)Shuichi Takayama (2 shared papers)Yu‐suke Torisawa (2 shared papers)Masanori Onda (14 shared papers)
- Journals
- Antibody Therapeutics (18 papers)Clinical Cancer Research (9 papers)Proceedings of the National Academy of Sciences (8 papers)Scientific Reports (6 papers)Molecular Cancer Therapeutics (5 papers)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
Mitchell Ho
136 papers receiving 7.4k citations
Mitchell Ho's Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 2.4k
- Immunology 1.7k
- Biotechnology 680
- Hepatology 506
- Radiology, Nuclear Medicine and Imaging 1.4k
Countries citing papers authored by Mitchell Ho
This map shows the geographic impact of Mitchell Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Ho more than expected).
Fields of papers citing papers by Mitchell Ho
This network shows the impact of papers produced by Mitchell Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Ho. The network helps show where Mitchell Ho may publish in the future.
Co-authors
The 25 scholars most cited alongside Mitchell Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 145 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array Hit paper breakdown → | 2010 | 826 |
| 2 | 2006 | 339 | |
| 3 | 2007 | 289 | |
| 4 | 2012 | 195 | |
| 5 | 2010 | 194 | |
| 6 | 2013 | 165 | |
| 7 | 2008 | 161 | |
| 8 | Cancer therapy with antibodies Hit paper breakdown → | 2024 | 152 |
| 9 | 2006 | 148 | |
| 10 | 2014 | 146 | |
| 11 | 2020 | 140 | |
| 12 | 2007 | 138 | |
| 13 | 2015 | 132 | |
| 14 | 2005 | 128 | |
| 15 | 2007 | 120 | |
| 16 | 2018 | 116 | |
| 17 | 2013 | 112 | |
| 18 | 2017 | 110 | |
| 19 | 2018 | 105 | |
| 20 | 2013 | 99 |
About Mitchell Ho
Mitchell Ho is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Biotechnology and Molecular Biology, having authored 145 papers that have together received 7.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (49 papers), CAR-T cell therapy research (43 papers), Toxin Mechanisms and Immunotoxins (28 papers), Glycosylation and Glycoproteins Research (26 papers), Occupational and environmental lung diseases (17 papers), Proteoglycans and glycosaminoglycans research (12 papers), Transgenic Plants and Applications (10 papers) and Immunotherapy and Immune Responses (10 papers). The work is most often cited by research in Oncology (2.4k citations), Immunology (1.7k citations), Biotechnology (680 citations), Hepatology (506 citations) and Radiology, Nuclear Medicine and Imaging (1.4k citations). Mitchell Ho has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Ira H Pastan, Raffit Hassan, Wei Gao, Heungnam Kim, Mingqian Feng, Shuichi Takayama, Yu‐suke Torisawa, Masanori Onda, Yi‐Chung Tung and Amy Y. Hsiao. Their work appears in journals such as Antibody Therapeutics, Clinical Cancer Research, Proceedings of the National Academy of Sciences, Scientific Reports and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.